Copied to clipboard!

The ITCC-P4 PDX platform of pediatric cancers for preclinical testing

Cancer is the leading cause of disease-related deaths among children in high-income countries. Tumor heterogeneity and lack of mechanism-of-action-based therapeutic options are key challenges to overcome in order to improve pediatric cancer patients’ survival. Here, we report the EU-IMI-2 funded public-private partnership “ITCC-Pediatric Preclinical Proof-of-Concept Platform” (ITCC-P4), which has built a large repertoire of patient-derived xenograft (PDX) models, representing all major solid pediatric cancer types, for in vivo drug testing. Three-hundred-fifty-three PDX models from diagnostic and relapsed pediatric cancers have been established and molecularly characterized, together with matched germline/tumor samples. As proof-of-concept, we present in vivo drug screening data in neuroblastoma and rhabdomyosarcoma models. PDX data, accessible at http://r2platform.com/itcc-p4, allow the selection of models based on oncogenic drivers and/or potential biomarkers for preclinical testing. Operated by a non-profit entity (www.itccp4.com), this sustainable platform aids academic and industrial researchers in developing and prioritizing innovative therapies for pediatric cancer.

Type: Other
Archiver: European Genome-phenome Archive (EGA)

3 Datasets

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD00001015774	This dataset contains 573 whole genome sequencing samples of patients with PDX primary and relapse tumors as well as blood control samples. Sequencing has been performed on Illumina HiSeq 2000, 2500, 4000, X and NovaSeq 6000. The sequencing has always been paired.	HiSeq X Ten Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000 Illumina NovaSeq 6000	572
EGAD00001015775	This dataset contains 792 whole exome sequencing samples of patients with PDX primary and relapse tumors as well as blood control samples. Sequencing has been performed on Illumina HiSeq 2000, 4000, X, NextSeq 500 and NovaSeq 6000. The sequencing has always been paired.	HiSeq X Ten Illumina HiSeq 2000 Illumina HiSeq 4000 Illumina NovaSeq 6000 NextSeq 500	785
EGAD00001015776	This dataset contains 189 transcriptome sequencing samples of patients with PDX primary and relapse tumors. Sequencing has been performed on Illumina HiSeq 4000, NextSeq 500 and NovaSeq 6000. The sequencing has always been paired.	Illumina HiSeq 4000 Illumina NovaSeq 6000 NextSeq 500	485